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The Artforce  (Adaptive and innovative Radiation Treatment 
FOR improving Cancer treatment outcomE) project is an EU 
7th Frame work funded project. The aims of this project are: 
1. To deliver higher tumour doses by redistributing the 
radiation dose towards highly positive in FDG-PET scans 
areas; 
2. Advanced treatment monitoring, in particular daily cone 
beam CT on the linear accelerator, repetitive FDG-PET 
imaging and electronic portal dosimetry;  
3. To validate specific predictors for tumour response to 
cisplatin and cetuximab and normal tissue complication;   
4. To improve strategies for biological and anatomical 
adaptive optimisation. 
This project includes two on-going randomized clinical trials, 
aiming at dose redistribution in head and neck and lung 
cancer.  
For these trials the following projects are carried out: 
Adaptive radiotherapy: P.I. Jan-Jakob Sonke 
All relevant imaging and planning data for improved outcome 
modelling and data mining were collected to account for 
anatomical changes. A method to update the geometrical 
patient model was developed and validated. Using 
deformable image registration of repeat cone beam CT 
(CBCT) scans acquired during the first part of the treatment, 
the original planning CT is deformed to the average patient 
model.  
Biological adaptive treatment planning P.I. Iuliana Dasu 
Assessment of the tumour responsiveness based on two 
successive FDG-PET scans, one taken at the planning stage, 
before the start of the treatment, and a second one taken 
during the second week of treatment, in relation to the 
delivered dose, was evaluated in 26 NSCLC patients. It 
showed that it is feasible to determine a threshold value for 
the effective radiosensitivity of the patients corresponding to 
good response.   
In vivo dosimetry: P.I Wouter van Elmpt 
Three dimensional (3-D) in-vivo dosimetry as an integrated 
quality assurance (QA) procedure to accurately verify dose 
delivery applicable to all the major teletherapy systems in 
the EU were developed, validated and implemented.  
Biomarkers: P.I. Eric Deutsch and Guido Kroemer 
Tumour biopsies are being collected to predict the sensitivity 
to cisplatin and the radiation response.  During the first 
period of the project we identified pyridoxal kinase (PDXK), 
the enzyme generating bioactive vitamin B6, as a prognostic 
marker in three independent cohorts of non-small cell lung 
carcinoma patients.  
Imaging: P.I. Philippe Lambin 
Visual analysis of 10 head and neck cancer patients showed 
heterogeneous uptake of  89Zr-labelled cetuximab within the 
Gross Tumour Volume (GTV).  An analysis in lung cancer 
patients of the overlap fractions and regions for both FDG- 
and HX4-PET scans revealed a positive correlation between 
FDG and HX4 uptake parameters on a GTV level.   
Lung cancer trial: P.I. Jose Belderbos and Dirk de Ruysscher 
End of 2014, 118 patients were registered and 78 
randomized.  
The toxicity assessed in November 2014 did not reveal 
unexpected or serious adverse events.   
Head and Neck cancer trial. P.I. Olga Hamming 
End of 2014, 32 patients have been randomized. 
Unfortunately, the supply of cetuximab free of charge was 
stopped (after May 2014) which necessitated a significant 
adaptation of the protocol.  
The toxicity analysis in March 2014 based upon the first 15 
patients demonstrated that all patients could finish their 
radiation treatment without delay. Acute toxicities are as 
expected from a curative chemoradiation treatment in the 
head and neck area. 
Participating centres: The Netherlands Cancer Institute, 
Amsterdam; Karolinska Institutet, Stockholm; Maastro Clinic, 
Maastricht; Val d’Hebron Hospital, Barcelona; INSERM, Paris; 
RaySearch, Stockholm; Christie Hospital, Manchester; Institut 
Gustave Roussy, Villejuif. 
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In the age of personalized medicine, information about the 
tumour characteristics guiding treatment decisions prior to 
and early during therapy is of crucial importance. While local 
extension of head and neck squamous cell carcinoma (HNSCC) 
is mainly assessed by physical examination and anatomical 
imaging, unfavourable tumour features such as hypoxia, 
proliferation rate and intrinsic radio-resistance are not 
reliably depicted. Therefore, the added value of molecular 
imaging with positron emission tomography (PET) is 
increasingly explored in head and neck tumours. Integration 
of PET techniques into therapy selection and adaptation 
strategies, as well as radiation treatment planning for 
HNSCC, can serve several purposes. First, pre-treatment 
assessments can steer decisions about radiotherapy 
modifications or combinations with other modalities. Second, 
biology-based objective functions can be introduced to the 
radiation treatment planning process by co-registration of 
molecular imaging with planning CT-scans. Thus, customized 
heterogeneous dose distributions can be generated with 
escalated doses to tumour subvolumes where radiotherapy 
resistance mechanisms are most prevalent. Third, monitoring 
of temporal and spatial variations in these radiotherapy 
resistance mechanisms early during the course of treatment 
can discriminate responders from non-responders. With such 
information available shortly after the start of treatment, 
modifications can be implemented or the radiation treatment 
plan can be adapted tailing the biological response pattern. 
The most commonly applied PET tracer - 18FDG - highlights 
volumes of increased cellular metabolism, but requires 
careful interpretation due to uptake in non-malignant tissues 
or peritumoral inflammation. Several studies have 
demonstrated a prognostic value of 18FDG PET imaging before 
and during therapy based on quantification or volumetric 
characteristics. Ongoing investigations evaluate utilization of 
18FDG signal as a basis for radiotherapy dose redistribution. 
A number of PET tracers associated with tumour cell hypoxia, 
e.g., 18FMISO and 18FAZA, have shown prognostic value and 
may guide individualized therapy, i.e., the addition of 
hypoxia-modulating agents or dose-escalation to radio-
resistant tumour subvolumes. 
18FLT-PET can be used repetitively to characterize tumour 
proliferation before and during treatment, facilitating 
adaptive radiotherapy and other tailored treatment 
strategies. Antibody-based PET tracers such as 89Zr-labeled 
cetuximab, specific to the epidermal growth factor receptor 
(EGFR), can be utilized for assessment of presence, 
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abundance and accessibility of specific targetable molecules 
and selection of patients who may benefit from the addition 
of targeted agents to radiotherapy. In the nearby future, the 
combination of tracers with a long and a short half-life may 
facilitate simultaneous imaging of different tumour 
characteristics. Furthermore, the introduction of integrated 
PET-MRI imaging will most likely provide a combination of 
superior anatomical and functional information. 
Small studies employing adaptive radiotherapy based on 
functional dynamics and early response mechanisms 
demonstrate promising results. However, each PET tracer has 
demonstrated its potential as well as pitfalls regarding 
application in everyday clinical practice. Further validation in 
multicenter set-up is needed. Immunohistochemistry and 
gene arrays may help to select which therapeutic pathway is 
most suitable for an individual tumour and, therefore, which 
type of molecular PET imaging will be relevant. Ultimately, 
this should result in availability for routine clinical practice 
requiring stable production and accessibility of tracers, 
reproducibility and standardization of imaging and analysis 
methods, as well as general availability of knowledge and 
expertise. 
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Clinical trials are an excellent tool for evaluating the 
effectiveness of a single change in patient management on 
later outcomes.  In the rapidly evolving landscape of clinical 
practice, a plethora of incremental changes may either exert 
a background effect, or be introduced during the conduct of 
a clinical trial.  These can have the effect of blunting, or 
even overwhelming, the impact of the intervention being 
assessed in a randomized study.  Using various examples from 
recently reported clinical trials investigating radiation dose 
escalation, we explore this phenomenon, and speculate on 
how future research may be able to adapt accordingly.  
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Purpose/Objective: Multimodal imaging has the potential to 
increase the accuracy of head and neck squamous cell 
carcinoma target volume delineation. This study aims to 
quantify the variation in Oropharyngeal Squamous Cell 
Carcinoma (OSCC) Gross Tumour Volume (GTV) delineation 
between CT, MR and 18FDG-PET imaging. 
Materials and Methods: A prospective, single centre, pilot 
study was undertaken where 11 patients with locally 
advanced OSCC (2 tonsil, 9 base of tongue primaries) 
underwent pre-treatment, contrast enhanced, 18FDG-PET-CT, 
and T1- and T2-weighted MR imaging, all performed in a 
radiotherapy treatment mask. GTVs were contoured by 6 
clinicians (2 radiologists and 4 radiation oncologists) using CT 
and MRI (T1 and T2 sequences) independently and co-
registered CT and MRI (rigidly co-registered using Mirada RTx 
v1.4, Mirada Medical, Oxford, UK). Clinical information and 
available diagnostic imaging was on hand during contouring. 
A 2 week gap was imposed between individual patient 
delineations to minimise recollection. The semi-automatic 
Schaefer adaptive algorithm contoured the 18FDG-PET GTVs. 
Volume and positional metrics assessed the GTV variation 
with imaging modality. Linear mixed effects models were 
used to determine GTV volume variations, accounting for 
inter-patient and inter-operator variability. Six delineation 
error metrics (described in table 1, ImSimQA, v3.1.5, OSL, 
Shrewsbury, UK) were used to determine the inter-observer 
variability in GTV position within modalities and the variation 
in GTV position between modalities. 
Results: Volumes: The mean GTV volumes were: CT 11.9cm3 
(SD = 4.5cm3); CT-MR 14.1cm3 (SD = 3.7cm3); MR 12.7 cm3 (SD 
= 2.5cm3); and 18FDG-PET 9.5cm3 (SD = 6.8cm3). Significant 
GTV volume differences were found between CT and CT-MR ( 
p < 0.0005), CT-MR and 18FDG-PET ( p < 0.0009) and MR and 
18FDG-PET ( p < 0.016) modalities. MR had a significantly 
smaller inter-operator variability ( p < 0.05) compared to CT. 
Figure 1 shows the GTV volumes for all patients for all 
modalities. 
Positional metrics: The CT inter-observer variability was 
found to be significantly higher ( p <0.05) than both MR and 
CT-MR modalities for all positional metrics except for the 
mean distance to conformity (Table 1). Differences in GTV 
position were found between all modalities with the 
exception of the positionally similar CT-MR and MR GTVs 
(Table 1). 
 
 
Conclusions: Inter-observer variation using MRI for GTV 
delineation was significantly less than when using CT. The 
use of different imaging modalities (CT, MR and 18FDG-PET) 
produced significantly different GTVs which varied in volume 
